51 results
8-K
EX-10.2
OPTN
OptiNose Inc
9 May 24
Optinose Announces $55 Million Registered Direct Offering
7:04am
to Section 404 of the Sarbanes-Oxley Act of 2002 attesting to management’s assessment that such internal controls meet the requirements of the Sarbanes
8-K
OPTN
OptiNose Inc
6 Dec 23
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
7:02am
and an assessment of the safety and efficacy of 186 or 372 mcg twice daily (the 2 currently approved and marketed doses for XHANCE) over a 24-week … symptom was scored from 0-3. The volume of the ethmoid and maxillary sinuses occupied by disease was assessed using computer-assisted assessment
PRE 14A
0xp5602w
21 Apr 23
Preliminary proxy
4:51pm
8-K
EX-1.1
sjkp 89z5s
23 Nov 22
Optinose Announces Proposed Public Offering of Common Stock and Warrants
4:09pm
8-K
EX-10.1
mu4n6i23
21 Nov 22
Entry into a Material Definitive Agreement
6:16am
8-K/A
EX-99.1
izr n40wu7ep2ta5ir
27 Sep 22
Departure of Directors or Certain Officers
4:38pm
8-K
EX-1.1
sp6jbws1on
18 Nov 21
Optinose Announces Proposed Public Offering of Common Stock
12:20pm